1294例女性高危型人乳头瘤病毒基因分型结果回顾性分析

目的了解北京地区妇科门诊就诊女性高危型人乳头瘤病毒(HPV)的感染及其基因亚型分布情况,为该市今后防治人乳头瘤病毒感染和宫颈癌提供参考依据。方法回顾性分析2013年1月至2014年5月该院妇科门诊就诊的1 294例女性宫颈拭子的13种高危型HPV基因分型检测结果,比较不同基因型的流行病学特点。采用SPSS17.0对数据进行统计学分析。结果 1 294例妇科门诊就诊女性中,以58型、16型和52型HPV最为常见,检出率分别为10.5%、9.2%和8.2%。各年龄段就诊女性中,30~40岁的HPV感染率最高(39.9%),其次为40~50岁、大于或等于60岁,差异无统计学意义(P0.05)。结论该地区妇科门诊就诊女性高危型HPV感染率较高,应加强HPV筛查力度,为今后HPV相关疾病的防治提供基础依据。     

高迁移率族蛋白B1靶向治疗的研究进展

高迁移率族蛋白B1 (HMGB1)为重要炎性因子,其为无菌性炎症与感染相关炎症反应的重要调节者,在感染、炎症及免疫反应中发挥重要作用.HMGB1表达水平可反映机体炎症及组织损伤的严重程度,且与相关疾病的预后密切相关.以HMGB1为治疗靶点,有望为感染、自身免疫性疾病、缺血再灌注损伤(IRI)、移植物抗宿主病(GVHD)等疾病的治疗提供潜在新策略.     

Alterations of gene profiles in Leydig-cell-regenerating adult rat testis after ethane dimethane sulfonate-treatment

Only occupying about 1%–5% of total testicular cells, the adult Leydig cell (ALC) is a unique endocrine cell that produces androgens. Rat Leydig cells regenerate after these cells in the testis are eliminated with ethane dimethane sulfonate (EDS). In this study, we have characterized Leydig cell regeneration and messenger ribonucleic acids (mRNA) profiles of EDS treated rat testes. Serum testosterone, testicular gene profiling and some steroidogenesis-related proteins were analyzed at 7, 21, 35 and 90 days after EDS treatment. Testicular testosterone levels declined to undetectable levels until 7 days after treatment and then started to recover. Seven days after treatment, 81 mRNAs were down-regulated greater than or equal to two-fold, with 48 becoming undetectable. These genes increased their expression 21 days and completely returned to normal levels 90 days after treatment. The undetectable genes include steroidogenic pathway proteins: steroidogenic acute regulatory protein, Scarb1, Cyp11a1, Cyp17a1, Hsd3b1, Cyp1b1 and Cyp2a1. Seven days after treatment, there were 89 mRNAs up-regulated two-fold or more including Pkib. These up-regulated mRNAs returned to normal 90 days after treatment. Cyp2a1 did not start to recover until 35 days after treatment, indicating that this gene is only expressed in ALCs not in the precursor cells. Quantitative polymerase chain reaction, western blotting and semi-quantitative immunohistochemical staining using tissue array confirmed the changes of several randomly picked genes and their proteins.     

A Comparison of Single-, Two- and Three-Port Laparoscopic Myomectomy

Background and Objective:

A recent FDA safety communication has discouraged the use of a power morcellator for myoma extraction and has called for a change in surgical techniques for myomectomy. The objective of this study was to compare surgical outcomes of laparoscopic single-, two-, and conventional three-port myomectomy and to evaluate the feasibility of contained manual morcellation for uterine myoma.

Methods:

This retrospective study was a review and analysis of data from 191 consecutive women who underwent single-, two-, or three-port myomectomy for the management of uterine myoma from January 1, 2009, through December 31, 2014.

Results:

The 3 study groups did not differ demographically. Apart from operative time, the single- and two-port groups showed operative outcomes comparable to those of the multiport group. The single-port group had significantly longer operative times (P = .0053) than the two- and three-port groups. However, in the latter half of the single-port cases, the operative time was similar to those in the three-port group. The two-port surgery group showed a consistent operative time without a learning period.

Conclusion:

Single- or two-port myomectomy with transumbilical myoma morcellation is feasible and safe, with outcomes comparable to those of three-port myomectomy. These results suggest the potential for minimally invasive management of symptomatic uterine myoma, without the use of a power morcellator.